Key result
2025 AHA/ACC hypertension guidelines introduce PREVENT equations and a 7.5% risk threshold for stage 1 therapy.
Why the study?
This review was conducted to examine the 2025 American Heart Association/American College of Cardiology multisociety hypertension guideline, place its recommendations in historical context, and evaluate the supporting evidence across major clinical populations.
The 2025 AHA/ACC hypertension guidelines advance a risk-based, measurement-dependent approach, emphasizing earlier pharmacotherapy for stage-1 hypertension and intensive targets for high-risk patients.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The 2025 AHA/ACC hypertension guidelines reemphasize HTN as the leading and most modifiable contributor to cardiovascular morbidity and mortality, while introducing several important updates from the 2017 recommendations.”
“The 2025 AHA/ACC hypertension guidelines are an important resource for the prevention, diagnosis, and management of hypertension and the optimization of therapy selection and patient safety across a wide variety of hypertensive conditions. Health care providers should stay up to date on recommendations from US and international organizations to optimize hypertension care for individual patients.”
May inform earlier stage-1 treatment via PREVENT thresholds; extends 2017 guidelines with race-free risk equations and selective intensive targets.
This review examines the 2025 American Heart Association/American College of Cardiology multisociety hypertension guideline, placing its recommendations in historical context and evaluating the supporting evidence across major clinical populations. The 2025 guideline retains the 2017 blood pressure categories and treatment goal of less than 130/80 mmHg but introduces the race-free PREVENT equations, uses a 7.5% 10-year risk threshold to guide pharmacologic treatment of stage-1 hypertension, and encourages systolic blood pressure below 120 mmHg in selected high-risk patients. Additional updates include single-pill combination therapy for stage-2 hypertension, broader primary aldosteronism screening, routine urine albumin-to-creatinine ratio measurement, removal of race-based drug selection, and cautious incorporation of renal denervation. Recent trials strengthen the evidence for intensive lowering, including in diabetes and older adults. The 2025 guideline advances a risk-based, measurement-dependent approach. The principal challenge is no longer identifying effective treatments but delivering accurate measurement, timely intensification, and sustained follow-up at scale.
No takes yet. Share an insight, caveat, or question.
Giacona et al. (2026) conducted a review in Hypertension. 2025 AHA/ACC Hypertension Guidelines vs. 2017 ACC/AHA Guidelines was evaluated. The 2025 AHA/ACC hypertension guidelines retain the <130/80 mmHg goal but introduce the PREVENT equations and a 7.5% 10-year risk threshold to guide pharmacologic treatment of stage-1 hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: